{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:09:03Z","timestamp":1775804943233,"version":"3.50.1"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005227","name":"Jilin Provincial Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Esophageal squamous cell carcinoma (ESCC) is a highly prevalent and aggressive malignancy worldwide, associated with poor prognosis. Most patients are diagnosed at an advanced stage, where conventional chemotherapy offers limited therapeutic efficacy and is often accompanied by substantial toxicity. In recent years, immune checkpoint inhibitors (ICIs), particularly those targeting PD-(L)1 and CTLA-4, have emerged as cornerstone therapies in both first-line and subsequent treatment settings for advanced ESCC. Nevertheless, significant clinical challenges persist, including the complexity of mechanisms underlying immune resistance, suboptimal predictive performance of existing biomarkers, difficulties in the management of immune-related adverse events (irAEs), and underrepresentation of elderly patients in clinical trials. This review summarizes recent advances in immunotherapy for advanced ESCC, evaluating the clinical evidence supporting ICIs as monotherapy or in combination with agents such as anti-angiogenic drugs and tyrosine kinase inhibitors. It further discusses the therapeutic potential of novel approaches, including bispecific antibodies, CAR-T cell therapy, and next-generation ICIs, while addressing current treatment paradigms for elderly patients. The importance of comprehensive, longitudinal management of irAEs is emphasized. Additionally, this article provides an in-depth analysis of mechanisms contributing to immune resistance\u2014such as loss of tumor neoantigens and dysregulation of key signaling pathways\u2014and critically appraises the limitations of established biomarkers, including PD-L1 expression and tumor mutational burden (TMB), alongside emerging developments in biomarker discovery. In conclusion, while immunotherapy has significantly improved outcomes and expanded therapeutic prospects for patients with advanced ESCC, further research is required to elucidate resistance mechanisms, refine treatment strategies, and identify robust predictive biomarkers. These efforts are essential to advance precision medicine in ESCC and ultimately enhance long-term survival outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1739762","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:20:55Z","timestamp":1775802055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances and challenges in immunotherapy for advanced esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Yishan","family":"Wang","sequence":"first","affiliation":[{"name":"The Affiliated Hospital of Jiangxi University of Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Oncology Translational Research Lab, Jilin Cancer Hospital","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Oncology Translational Research Lab, Jilin Cancer Hospital","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Jiangxi University of Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Jilin Cancer Hospital","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.02.01","article-title":"Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)","volume":"31","author":"National Health Commission Of The People's Republic Of C","year":"2019","journal-title":"Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328233","article-title":"Population-based investigation of common and deviating patterns of gastric cancer and esophageal cancer incidence across populations and time","volume":"72","author":"Li","year":"2023","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The epidemiology of esophageal adenocarcinoma","volume":"154","author":"Coleman","year":"2018","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s112038","article-title":"Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database","volume":"9","author":"Lin","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12457","article-title":"Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000-2014 (CONCORD-3)","volume":"43","author":"Matz","year":"2023","journal-title":"Cancer Commun (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): a global, randomized, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.74.9846","article-title":"Safety and antitumor activity of the anti\u2013programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30181-x","article-title":"Nivolumab treatment for esophageal squamous-cell carcinoma: an open-label, multicenter, phase 2 trial","volume":"18","author":"Kudo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicenter, randomized, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCORT): a multicenter, randomized, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","article-title":"An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14885","article-title":"The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma","volume":"14","author":"Xin","year":"2023","journal-title":"Thorac Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.06.07","article-title":"Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma","volume":"31","author":"Zhang","year":"2019","journal-title":"Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.218","article-title":"Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): a retrospective exploratory study","volume":"34","author":"Huang","year":"2023","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114328","article-title":"Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study","volume":"212","author":"Meng","year":"2024","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35377","article-title":"Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: a prospective phase 1b cohort study","volume":"130","author":"Ning","year":"2024","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12621","article-title":"HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: a phase 2 study","volume":"44","author":"Liu","year":"2024","journal-title":"Cancer Commun (London England)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e16005","article-title":"Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: a single-arm, open-label phase II clinical trial","volume":"43","author":"Xia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1359","article-title":"1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: tolerability results and antitumor activity in esophageal carcinoma","volume":"33","author":"Muro","year":"2022","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090884","article-title":"Research and clinical landscape of bispecific antibodies for the treatment of solid Malignancies","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharm (Basel Switzerland)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00411-4","article-title":"Safety and antitumor activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumors (COMPASSION-03): a multicenter, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf144","article-title":"First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors","volume":"30","author":"Gutierrez","year":"2025","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-7568(22)00116-7","article-title":"Second-line therapy with nivolumab plus ipilimumab for older patients with esophageal squamous cell cancer (RAMONA): a multicenter, open-label phase 2 trial","volume":"3","author":"Ebert","year":"2022","journal-title":"Lancet Healthy Longevity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.201006432011512c","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S621","DOI":"10.1016\/j.annonc.2023.09.2159","article-title":"1020MO AdvanTIG-203: phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent\/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity","volume":"34","author":"Wang","year":"2023","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced esophageal cancer (KEYNOTE-590): a randomized, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (London England)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02797-y","article-title":"First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ORIENT-15): multicenter, randomized, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100380","article-title":"Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score","volume":"7","author":"Leone","year":"2022","journal-title":"ESMO Open"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00401-2","article-title":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable esophageal squamous cell carcinoma (SKYSCRAPER-08): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Hsu","year":"2026","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012869","article-title":"Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial","volume":"13","author":"Qu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1200\/jco.2025.43.4_suppl.411","article-title":"Bifunctional anti-PD-L1\/TGF-\u03b2RII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): survival results of a phase II trial","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.094","article-title":"LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: the randomized phase III LEAP-014 study","volume":"36","author":"Sun","year":"2025","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic esophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomized, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-025-02376-w","article-title":"Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial","volume":"24","author":"Meng","year":"2025","journal-title":"Mol Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/itt.s126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"ImmunoTargets Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: Obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2020","journal-title":"CA: A Cancer J For Clin"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.74.9846","article-title":"Safety and antitumor activity of the anti\u2013programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.4166\/kjg.2018.71.3.116","article-title":"Esophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet (London England)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma","volume":"66","author":"Thompson","year":"2017","journal-title":"Gut"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0000000000000941","article-title":"Intrapatient tumor heterogeneity in IHC interpretation using PD-L1 IHC 22C3 pharmDx","volume":"29","author":"Kalpakoff","year":"2021","journal-title":"Appl Immunohistochemistry Mol Morphology: AIMM"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05595-0","article-title":"Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)","volume":"150","author":"Wang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00752-x","article-title":"Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1 therapy benefit and prognosis in microsatellite-stable cancers","volume":"5","author":"Muquith","year":"2024","journal-title":"Nat Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01818","article-title":"NOTCH1 mutation and survival analysis of tislelizumab in advanced or metastatic esophageal squamous cell carcinoma: A biomarker analysis from the randomized, phase III, RATIONALE-302 trial","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","article-title":"Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41467-024-46307-7","article-title":"Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14610","article-title":"Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma","volume":"13","author":"Yang","year":"2022","journal-title":"Thorac Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12885-022-09846-0","article-title":"Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial","volume":"22","author":"Yu","year":"2022","journal-title":"BMC Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06740-2","article-title":"Circulating microRNAs in relation to esophageal adenocarcinoma diagnosis and survival","volume":"66","author":"Petrick","year":"2021","journal-title":"Digestive Dis Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: Advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30445-9","article-title":"Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.02.019","article-title":"Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions","volume":"86","author":"Haddad","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1946","article-title":"Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition","volume":"23","author":"Pereira","year":"2017","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-s3-o15","article-title":"Melanoma-intrinsic \u03b2-catenin signaling prevents anti-tumor immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-1439","article-title":"JAK mutations as escape mechanisms to anti-PD-1 therapy","volume":"7","author":"Marabelle","year":"2017","journal-title":"Cancer Discov"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28444","article-title":"Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway","volume":"120","author":"Zhang","year":"2019","journal-title":"J Cell Biochem"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s42003-024-07341-9","article-title":"EZH2 elicits CD8(+) T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells","volume":"7","author":"Zhu","year":"2024","journal-title":"Commun Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202000391","article-title":"Epigenetics in esophageal cancer: From mechanisms to therapeutics","volume":"4","author":"Liao","year":"2020","journal-title":"Small Methods"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.196.supp.213.20","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumor immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1186\/s12885-021-08702-x","article-title":"The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors","volume":"21","author":"Bissonnette","year":"2021","journal-title":"BMC Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10495-025-02256-0","article-title":"Progenitor CD8(+) T cells and hyper-Treg crosstalk: A driver of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma","volume":"31","author":"Huang","year":"2026","journal-title":"Apoptosis: Int J Programmed Cell Death"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.7150\/thno.118269","article-title":"MIF-expressing tumor cells mediate immunotherapeutic resistance in esophageal squamous cell carcinoma","volume":"16","author":"Song","year":"2026","journal-title":"Theranostics"},{"key":"B93","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41392-023-01388-6","article-title":"Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.942678","article-title":"Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med Oncol (Northwood London England)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8167","article-title":"Plasma-derived exosomal pyruvate kinase isoenzyme type M2 accelerates the proliferation and motility of esophageal squamous cell carcinoma cells","volume":"46","author":"Yang","year":"2021","journal-title":"Oncol Rep"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s106508","article-title":"Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies","volume":"9","author":"Wu","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/jgo-21-50","article-title":"CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma","volume":"12","author":"Yue","year":"2021","journal-title":"J Gastrointestinal Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0348","article-title":"A systematic review of metabolomic profiling of gastric cancer and esophageal cancer","volume":"17","author":"Huang","year":"2020","journal-title":"Cancer Biol Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1739762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:20:56Z","timestamp":1775802056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1739762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2026.1739762"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1739762","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1739762"}}